Big pharma's interest in using protein degradation as a therapeutic strategy continues with a wide-ranging deal between Pfizer and US biotech Triana Biomedicines that could be worth $1.5 billion or ...
As the industry has transitioned much of its R&D expertise into large molecule therapies, an emerging approach could provide a revolutionary treatment tool. Ben Hargreaves investigates why molecular ...
Abstract: Unmanned aerial vehicles (UAVs) have found numerous applications and are expected to bring fertile business opportunities in the next decade. Among various enabling technologies for UAVs, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results